No Data
J.P. Morgan Sticks to Their Hold Rating for Vir Biotechnology (VIR)
Leerink Partners Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $18
Following the US Secretary of Health, Trump's nomination for the FDA Commissioner seems to be another anti-vaccine advocate.
Makari is a surgeon who opposes overtreatment, advocates for re-evaluating hormone replacement therapy, and reducing the overuse of antibiotics.
HC Wainwright & Co. Reiterates Buy on Vir Biotechnology, Maintains $110 Price Target
TD Cowen Maintains Vir Biotechnology(VIR.US) With Buy Rating
A Quick Look at Today's Ratings for Vir Biotechnology(VIR.US), With a Forecast Between $10 to $26